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Large randomized trials on critically ill patients have related the use of hydroxyethyl starch (HES) to negative
outcomes. In a recent comment we explained in detail why, from our point of view, transferring the results of
VISEP, 6S and CHEST into daily ICU practice is as difficult as their extrapolation to perioperative treatment. Haase,
Müller and Perner lately challenged this analysis. However, after having carefully read their letter to the editor we
are happy to demonstrate that all points we made were absolutely correct. We agree with Haase et al. that a
debate on HES safety is important, but has to be based on facts. The difference might be that we like to thoroughly
discuss all of them, including the main one: VISEP, 6S and CHEST do not capture the initial stabilization of their
hemodynamically instable patients. The vast majority, including those patients later assigned to the “crystalloid”
groups, had been stabilized with colloids before study onset. This is not a big problem, but has to be discussed
carefully and honestly to prevent the data from being misinterpreted by users and official authorities.
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Aldous Huxley 1929.
We are grateful to Drs. Haase, Müller and Perner for
their interest in our thoughts and happy that we agree in
their major point: discussions on hydroxyethyl starch
(HES) are important, but have to be based on facts [1].
Unfortunately, their reply might arouse the suspicion to
the reader that our comment [2] was not accurate. This
is certainly not the case, all numbers and statements were
correct. We are happy to provide some help concerning
the facts in this discussion.
First, Haase et al. ignore the fact that fresh frozen
plasma (FFP) contains albumin and other macromolecules
and, therefore, is a colloid. Taking this into account, in
6S [3] the majority of the patients in the crystalloid
group received in fact up to 1 liter of colloids (HES,
albumin and/or FFP) for initial stabilization before the
trial started. After that, 1/3 of this “crystalloid” group
additionally received a colloid during the interventional
period. Therefore, 6S is in fact not a trial purely comparing
crystalloid vs. colloid, but colloid in a usual vs. colloid in an
unusual way. As to be expected, the usual way - infusing a* Correspondence: matthias.jacob@med.uni-muenchen.de
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article, unless otherwise stated.considerable amount of colloid in the first hours of severe
sepsis before switching to a crystalloidal-based maintenance
protocol - led to a significantly better survival. We (and
many others worldwide) cannot understand how this
can lead to the conclusion that one of these applied
colloids should be generally abandoned. The bottom
line of Haase et al. does not reflect their results, as over
75% of all patients in their trial received HES.
Haase et al. state that neither they nor we could know
what the doctors were doing in detail during the trial,
especially what their decision to infuse the study fluid
or not was based on in the individual case. We are
afraid this is insufficient to serve as a reliable reference
for worldwide future behavior. How should anybody
recapture what happened to the patients if even the
authors can not? How can the authors draw their
incomprehensible conclusions without knowing what
exactly happened? From studies which want to change our
behavior around hemodynamic optimization a protocol
including basic and extended hemodynamical monitoring,
a careful documentation of the need of vasopressors/
inotropic agents and criteria for implementing, e.g., renal
replacement therapy is absolutely necessary.
Nevertheless, we agree that 6S indicates how well the
participating doctors were trained: They infused colloidsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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their patients.
The next point our comment criticized was the fact that
the duration of ICU stay was not reported. According to
the opinion of Haase et al., the aspect “alive and out of
hospital” chosen instead would provide more information,
as it might be “less affected by survival bias”. However,
a fact is that the patients received trial treatment during
their entire ICU stay. Therefore, length of ICU stay is the
only number which can tell us how long patients were
treated with the respective drug. Despite being a nice
additional information, the provided alternative is no
scientifically adequate replacement.
It is an interesting explanation for the fact that over 1/
3 of the patients received a contraindicated drug that
the steering committee, scientific advisors and Medicine
Agencies approved the protocol. We are convinced that
approval does not release from medical responsibility
and, therefore, does not justify to ignore the fact that
renal failure was already a contraindication for HES (stated
e.g. by the American FDA [4]) before 6S was initiated
and it still is one today. Even if the authors believe
this inclusion to be ethical, we would at least expect
a subgroup analysis excluding these patients.
We agree with Haase et al. that it takes time to identify
“severe sepsis” and to fulfill all the regulatory requirements.
Accordingly, an earlier inclusion of septic patients into
double-blinded prospective studies is hardly possible.
However, this does not justify a discussion ignoring their
major weakness: the fact that colloids (predominantly
HES) were used in the vast majority of patients to reach
the hemodynamical target criteria of the Surviving Sepsis
Campaign [5] before study treatment started, also in those
of the later “crystalloid” groups. Moreover, it is important
to discuss the fact that in 1/3 of the “crystalloid” group
colloids were also infused during the trial. Again, a sub-
group analysis would have been quite informative here.
In this context it is interesting that the recently pub-
lished CRISTAL-study [6], a randomized open label trial
on 2,857 patients in hypovolemic shock for various reasons
(sepsis, trauma, or without sepsis or trauma), included the
crucial first 6 hours of resuscitation [7] into the treatment
protocol, showing completely different results. Treating the
patient with any kind of colloid (starch, gelatin or albumin)
compared to any kind of crystalloid, CRISTAL showed
an improved 90-day survival, fewer days of mechanical
ventilation and less need of vasopressors in the colloid
group. No differences in the incidence of organ failure or
renal replacement therapy were detected [6]. The strategy
of CRISTAL to combine different patient collectives
and different colloids into one analysis may not be
ideal. However, this study shows, for the first time, that
an indication-based use of colloids - by the way: the
majority of “colloid”-patients received a 3rd generationHES - might be advantageous to patients. In our opinion
this is at least as helpful as demonstrating a probably
artificial problem related to the continuous use of
HES in large amounts after stabilization, i.e., the use
of a potent drug in a way that is not well established
in clinical practice.
Last but not least Haase et al. declare that “safer ways
of using HES in critically ill patients have not yet been
identified”. This is astonishing. First, in their own trial
early hemodynamical stabilization was performed with
HES and other colloids. This obviously was the basis
of outcome success even in their septic patients who
received crystalloids later on. A pure crystalloidal therapy
from the very beginning of stabilization was not evaluated
in any group of 6S. Therefore, there is no scientific basis
of the author’s recommendation to principally rely on
such a strategy in the future. Beyond that, there are
clear hints in literature showing that a perioperative
goal-directed therapy using HES during major surgery
reduced postoperative complication rates, hospital stay
and morbidity.
Nevertheless, we agree with Haase et al. that in 2013
no patient should be treated with HES following initial
stabilization, especially in sepsis. As a fact, this is what
6S actually shows.
We are grateful to each scientist who runs a large
RCT addressing fluid and volume handling. However,
twisting facts, ignoring contraindications, hiding vital
information and over-interpreting results is not helpful
to advance the scientific discussion. Rather, it is dangerous
for the patients. It is not surprising that, after having
carefully reconsidered also the latest data with the help
of independent experts the Pharmacovigilance Risk
Assessment Committe (PRAC) of the European Medicines
Agency (EMA) revised its first decision from June
markedly. This initiated the Coordination Group for
Mutual Recognition and Decentralized Procedures -
Human (CMDh) in October to vote for maintaining
hydroxyethyl starches on the market for treatment of
hypovolemia due to acute bleeding. Very soon, the
European commission will make a final decision and
it is most likely that it will be close to the CMDh-
recommendation. The planned restrictions for septic,
critically ill and burned patients are sensible and
comprehensible. However, until today there are no
high quality data supporting that for the initial
stabilization phase in shock for any reason.
Received: 29 November 2013 Accepted: 2 December 2013
Published: 9 December 2013
References
1. Haase N, Müller R, Perner A: Debate on HES safety is important but must
be based on facts. Scand J Trauma Resusc Emerg Med 2013, 21:66.
2. Chappell D, Jacob M: Hydroxyethyl starch - the importance of being earn-
est. Scand J Trauma Resusc Emerg Med 2013, 21:61.
Chappell and Jacob Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2013, 21:85 Page 3 of 3
http://www.sjtrem.com/content/21/1/853. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A,
Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, et al: Hydroxyethyl starch
130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012,
367:124–134.
4. Press Release of the U.S. Food and Drug Administration (FDA): December 27,
2007: FDA Approves Voluven to Treat Serious Blood Volume Loss following
Surgery. [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
2007/ucm109048.htm]
5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky
JE, Sprung CL, Douglas IS, Jaeschke R, et al: Surviving sepsis campaign:
international guidelines for management of severe sepsis and septic
shock, 2012. Intensive Care Med 2013, 39:165–228.
6. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declère AD, Preiser JC,
Outin H, Troché G, Charpentier C, et al: Effects of fluid resuscitation with
colloids vs crystalloids on mortality in critically ill patients presenting
with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013,
310:1809–1817.
7. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E,
Tomlanovich M: Early goal-directed therapy in the treatment of severe
sepsis and septic shock. N Engl J Med 2001, 345:1368–1377.
doi:10.1186/1757-7241-21-85
Cite this article as: Chappell and Jacob: Twisting and ignoring facts on
hydroxyethyl starch is not very helpful. Scandinavian Journal of Trauma,
Resuscitation and Emergency Medicine 2013 21:85.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
